EUCTR2012-000482-21-Outside-EU/EEA进行中（未招募）不适用
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS GIVEN WITH ROUTINE PEDIATRIC VACCINATIONS IN HEALTHY INFANTS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject’s parent(s)/legal guardian(s) has been informed of all pertinent aspects of the study. If the subject’s parent(s)/legal guardian(s) is illiterate they must thumbprint the ICD and it must be signed and dated by an impartial witness who was present throughout the entire informed consent process.
- •2. Aged 42 to 70 days at time of enrollment.
- •3. Available for entire study period.
- •4. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.
- •5. Parent(s)/legal guardian(s) is willing and able to comply with scheduled visits and other study procedures.
- •6. Weight of 3.5 kg or greater at the time of enrollment.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 500
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous vaccination with licensed or investigational pneumococcal vaccine.
- •2. A previous anaphylactic reaction to any vaccine or vaccine-related component.
- •3. Contraindication to vaccination with pneumococcal conjugate vaccine.
- •4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
- •5. Known or suspected immune deficiency or suppression.
- •6. History of culture-proven invasive disease caused by Streptococcus pneumoniae.
- •7. Major known congenital malformation or serious chronic disorder.
- •8. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Does not include resolving syndromes due to birth trauma, such as Erb’s palsy.
- •9. Receipt of blood products or gamma-globulin since birth and until the blood draw approximately 1 month after the last dose of 13vPnC.
- •10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •11. Participation in other studies within 28 days before the current study begins and/or during study participation. Participation in observational studies, and interventional studies such as those where a nasopharyngeal swab or urine sample may be collected, are permitted.
- •12. Subjects who are direct descendents (child or grandchild) of investigational site staff members or Pfizer employees directly involved in the conduct of the trial.
研究者
相似试验
进行中（未招募）
1 期
A trial to evaluate the safety and immune response of a pneumococcal conjugate vaccine in adults ?65 years old with previous pneumococcal vaccinatioPneumococcal InfectionsMedDRA version: 20.0Level: PTClassification code 10069578Term: Pneumococcal immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-004278-91-SEPfizer Inc., 235 East 42nd Street, New York, NY 10017875
进行中（未招募）
1 期
A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.CUTANEOUS T CELL LYMPHOMA.EUCTR2004-003701-24-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
进行中（未招募）
不适用
Trial of Aeroquin versus Tobramycin Inhalation Solution(TIS) in Stable Cystic Fibrosis PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.1Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-IEMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.0 Level: PT Classification code 10011763 Term: Cystic fibrosis lung System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.0 Level: LLT Classification code 10021860 Term: Infection pseudomonas aeruginosa System Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-GBMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy ofMP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution(TIS) in Stable Cystic Fibrosis PatientsEUCTR2010-019634-26-FRMpex Pharmaceuticals, Inc.330